Angle Plc (AGL.L) Announced positive results from its Parsortix FDA clinical study for metastatic breast cancer. The Study has achieved its primary objective to demonstrate the ability of the Parsortix system to capture and harvest cancer cells from the blood of a significant proportion of metastatic breast cancer patients.
Login or register to post comments